PBF Logistics (NASDAQ:PBFX) had its price target cut by Barclays from $32.00 to $29.00 in a research note issued to investors on Friday. The firm currently has an overweight rating on the stock. PBF Logistics LP (NYSE:PBFX) belongs to Basic Materials sector. Its net profit margin is 43.60% and weekly performance is 10.44%. On last trading day company shares ended up $21.37. PBF Logistics LP (NYSE:PBFX) distance from 50-day simple moving average (SMA50) is -6.58%.
Clearwater Paper Corp (NYSE:CLW) on Tuesday said it sold its specialty products business and mills to Dunn Paper Inc. The company plans to reinvest the net proceeds of the sale into capital projects within its Consumer Products Division. Clearwater Paper Corporation (NYSE:CLW) belongs to Consumer Goods sector. Its net profit margin is 5.50% and weekly performance is -1.06%. On last trading day company shares ended up $68.16. Clearwater Paper Corporation (NYSE:CLW) distance from 50-day simple moving average (SMA50) is 1.36%.
Lime Energy Co. (NASDAQ:LIME), announced that the company has completed a capital raise for $10 million in gross proceeds before offering expenses. The funding comes from Bison Capital, a highly regarded private equity firm with a track record of helping innovative, growth-oriented companies like Lime Energy realize their potential. Lime Energy Co. (NASDAQ:LIME) shares fell -5.12% in last trading session and ended the day at $2.41. LIME Gross Margin is 30.10% and its return on assets is -32.40%. Lime Energy Co. (NASDAQ:LIME) quarterly performance is -25.39%.
Charlotte-based CommunityOne (NASDAQ: COB), the holding company of Asheboro-based CommunityOne Bank, says it sold common stock in a private placement at a discounted price of $10.56 per share. Outstanding shares closed Tuesday at $11.45. On 30 December, CommunityOne Bancorp (NASDAQ:COB) shares fell -0.26% and was closed at $11.45. COB EPS growth in last 5 year was 83.20%. CommunityOne Bancorp (NASDAQ:COB) year to date (YTD) performance is -10.20%.
NephroGenex, Inc. (NASDAQ:NRX), announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities. NephroGenex, Inc. (NASDAQ:NRX) ended the last trading day at $4.65. Company weekly volatility is calculated as 3.21% and price to cash ratio as 1.55. NephroGenex, Inc. (NASDAQ:NRX) showed a weekly performance of -0.21%.